IV selexipag can be used as a bridging therapy

PHA Canada
Jun 9, 2025
1 min read

Pulmonary arterial hypertension patients who take selexipag normally take it orally (as a pill). Sometimes, though, this is temporarily impossible. People might be unable to swallow or have other medical conditions that interfere with their ability to take pills. A small study looked at whether temporarily giving selexipag as an intravenous infusion was safe and effective. They found that it was.

Read the Therapeutics and Clinical Risk Management paper

Recent Posts

Sotatercept lowers blood volume but increases exercise ability

In a study of a relatively low-risk population of pulmonary hypertension patients, researchers began to untangle sotatercept's complex effects on exercise. Sotatercept lowered blood volume to normal l

AI May Help Predict PAH Patients' Risk of Worsening

Researchers looked at the medical records of 455 people with pulmonary arterial hypertension (PAH) to find factors associated with getting worse. Using a machine-learning computer model, they found 11

Sotatercept and cardiopulmonary comorbidities

This study from one clinic examined how well sotatercept worked in real-world patients with pulmonary arterial hypertension (PAH) who also had other heart or lung conditions, such as coronary artery d

Comments